Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Praxis Precision Medicines Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming conferences.

  • Praxis management will participate in a fireside chat at the H.C. Wainwright 2 nd Annual BioConnect Investor Conference, taking place in New York, NY at the NASDAQ Stock Exchange on May 20, 2024 at 10:00am EDT. A live webcast of the fireside chat will be available through this link and will also be available through the "Upcoming & Recent Events" page of the Investors + Media section of the company's website www.praxismedicines.com . A replay of the webcast will be available on Praxis' website for 90 days following the event.

  • Praxis management will also participate in the Mizuho Securities USA Neuroscience Summit, taking place in Boston, MA on May 21, 2024.

  • Praxis management will also be participating in a fireside chat at the Jefferies Global Healthcare Conference, taking place in New York, NY on June 6, 2024 at 11:30am EDT. A live webcast of the fireside chat will be available through this link and will also be available through the "Upcoming & Recent Events" page of the Investors + Media section of the company's website www.praxismedicines.com . A replay of the webcast will be available on Praxis' website for 90 days following the event.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook , LinkedIn and Twitter/X .


Investor Contact:  Praxis Precision Medicines  investors@praxismedicines.com  857-702-9452  Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

PRAX
The Conversation (0)
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results

Plans to initiate two efficacy studies investigating PRAX-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively

Continued strong recruitment for the pivotal Essential3 trials in Essential Tremor (ET), with over 50,000 pre-screening forms and over 7,000 referrals received to date that meet pre-qualifying eligibility criteria; topline results expected in the second half of 2024

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024

Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024

Praxis Precision Medicines Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will report financial results for the first quarter 2024 on Monday, May 13, 2024, before the U.S. financial markets open.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook , LinkedIn and Twitter/X .

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635

Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on May 1, 2024, the Compensation Committee of Praxis' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 7,800 shares of its common stock and restricted stock unit awards covering an aggregate of 5,851 shares of its common stock to six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The stock options and restricted stock units were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension  of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies

Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies

  • Bexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treatment period; participants randomized to the PACIFIC placebo group achieved a median seizure reduction of 57.3%
  • Favorable safety and tolerability results observed
  • 100% of participants who completed the PACIFIC Study entered the OLE
  • End of Phase 2 Meeting scheduled for this summer

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive interim results from its ongoing 52-week open-label extension of the PACIFIC Study evaluating bexicaserin (LP352) in participants ages 12-65 years old with Developmental and Epileptic Encephalopathies.

"We are thrilled to see a sustained, durable response in seizure reduction and a favorable safety and tolerability profile across a broad range of DEE patients. Additionally, we saw compelling seizure reduction in the PACIFIC placebo patients who transitioned to bexicaserin in the OLE. These data provide further support to bexicaserin's potential to offer a highly differentiated and best-in-class profile," stated Dr. Randall Kaye, Longboard's Chief Medical Officer.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver  in Milan

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver in Milan

SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models

Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated in healthy volunteers and patients with a history of liver cirrhosis

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Annexon Announces Pricing of $125 Million Underwritten Public Offering

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public offering of 13,001,120 shares of its common stock at a price to the public of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 7,000,000 shares of common stock at a purchase price of $6.249 per share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (INKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 12, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET.

To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/INKT2024 and enter the 16-digit control number found in their proxy materials. Guests may also access the meeting in listen-only mode. No control number is required for guests.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024

97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study

EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barrier to Resistance

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from six poster presentations at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy.

The clinical poster presentations highlight the continued potent antiviral activity of ALG-000184 for chronic hepatitis B (CHB) in both HBeAg-positive and HBeAg-negative subjects.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×